Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q3 2022 · 10-Q
Revenue$259.77M$259.77M+8.1% vs Q3 2021 Net Income$23.23M$23.23M−27.1% vs Q3 2021 EPS Diluted$0.45$0.45−27.4% vs Q3 2021 Gross Profit$138,565,000+15.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$62,433,000−5.8% Free Cash Flowderived$35,770,000−37.2% Margins · derivedGross margin53.3%+3.3 pt vs Q3 2021
Operating margin13.7%−3.1 pt vs Q3 2021
Net margin8.9%−4.3 pt vs Q3 2021
ended Jan 1, 2022 · filed Feb 8, 2022 · 38 d after period end